clofarabine has been researched along with raltegravir in 2 studies
| Studies (clofarabine) | Trials (clofarabine) | Recent Studies (post-2010) (clofarabine) | Studies (raltegravir) | Trials (raltegravir) | Recent Studies (post-2010) (raltegravir) |
|---|---|---|---|---|---|
| 424 | 101 | 280 | 100 | 9 | 73 |
| Protein | Taxonomy | clofarabine (IC50) | raltegravir (IC50) |
|---|---|---|---|
| Gag-Pol polyprotein | HIV-1 M:B_HXB2R | 0.015 | |
| Integrase | Human immunodeficiency virus 1 | 0.1953 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bonnac, L; Clouser, CL; Daly, MB; Kim, B; Landman, SR; Mansky, LM; Patterson, SE; Rawson, JM; Reilly, CS; Roth, ME; Xie, J | 1 |
1 review(s) available for clofarabine and raltegravir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for clofarabine and raltegravir
| Article | Year |
|---|---|
Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
Topics: Anti-HIV Agents; Azacitidine; Dose-Response Relationship, Drug; Enzyme Inhibitors; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Ribonucleotide Reductases; Structure-Activity Relationship | 2016 |